Although these studies utilizing RIPK2 inhibitors have not clearly shown whether such small molecules suppressed the activity of the NOD2–RIPK2 and TLRs–RIPK2 pathways to improve inflammation, their therapeutic and preventive effects seen in experimental IBD allow considering RIPK2 as a new therapeutic target in human IBD. This evidence concerns the gene RIPK2 and inflammatory bowel disease.